DaVita to Present Twelve Posters and One Oral Presentation at American Society of Nephrology Kidney Week

  DaVita to Present Twelve Posters and One Oral Presentation at American
  Society of Nephrology Kidney Week

Business Wire

SAN DIEGO -- October 31, 2012

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services committed
to improving the quality of life for those diagnosed with chronic kidney
disease (CKD), will present 13 abstracts at the American Society of Nephrology
(ASN) Kidney Week in San Diego, November 1-4. Attendees can find DaVita®
representatives in booth #1903.

ASN’s annual Kidney Week provides a valuable opportunity for more than 13,000
kidney care professionals from around the world to share and discuss new
developments related to all aspects of nephrology.

“Our goal at DaVita – in collaboration with our partners – is to advance the
knowledge and practice of kidney care,” said DaVita Vice President of DaVita
Clinical Research® Mahesh Krishnan. “The work we will share at ASN will, we
hope, lead to better clinical outcomes and better quality of life for CKD and
end-stage renal disease patients around the world.”

Researchers from DaVita and DaVita Clinical Research ^ (DCR®) will present
results from a number of innovative clinical improvement programs and health
economic studies originating from DaVita and its research partners. DCR
provides a collaborative bridge between DaVita services and the academic,
pharmaceutical, and biotech research community. DCR shares DaVita’s dedication
to improving the health and quality of life for kidney patients.

ASN Kidney Week abstract highlights include the following:

  *Extracellular Volume Control in Dialysis Patients To Reduce
    Hospitalizations (oral presentation FR-OR026 of joint study between
    DaVita, Fresenius Medical Care, and Renal Ventures, LLL; to be presented
    by Thomas Parker, M.D., Renal Ventures Management, LLC)
  *Analysis of the 2014 Quality Improvement Program Reporting Measures for
    Calcium Phosphate in Dialysis Patients (Nissenson et al, abstract
    SA-PO268)
  *Hemoglobin Trends in Incident End-Stage Renal Disease (ESRD) Patients from
    2008-2011 (Weldon et al, abstract FR-PO222)
  *Changing Hemoglobin Targets: Effects on Epoetin Alfa, Intravenous Iron,
    and Iron Storage Measures From 2009–2012 (Bond et al, abstract TH-PO822)
  *A Comparative Analysis of Transfusion Trends between Types of Providers of
    Dialysis Services Using Medicare Claims Data (Krishnan et al, abstract
    FR-PO263)

DaVita, DaVita Clinical Research and DCR registered trademarks of DaVita Inc.
All other trademarks are the property of their respective owners.

About DaVita

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in
the United States, delivering dialysis services to patients with chronic
kidney failure and end stage renal disease. DaVita strives to improve
patients’ quality of life by innovating clinical care, and by offering
integrated treatment plans, personalized care teams and convenient
health-management services. As of September 30, 2012, DaVita operated or
provided administrative services at 1,912 outpatient dialysis centers located
in the United States serving approximately 150,000 patients. The company also
operated 24 outpatient dialysis centers located in five countries outside the
United States. DaVita supports numerous programs dedicated to creating
positive, sustainable change in communities around the world. The company’s
leadership development initiatives and social responsibility efforts have been
recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more
information, please visitwww.davita.com.

About DaVita Clinical Research (DCR)

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is 
committed to advancing the knowledge and practice of kidney care. DCR brings
knowledge, skill and expertise to pharmaceutical research, facilitating the
success of its clients’ clinical trials. DCR’s clinical expertise spans the
lifecycle of drug development. DCR’s biorepository, Early Clinical Research
unit (Phase I-IIa) and Clinical Development network of physicians and
investigative sites, data research, Health Economics & Outcomes Research,
Central Laboratory, Advisory Committee prep, and Medical Communications are
focused on providing world-class clinical research in both complex/specialty
populations and therapeutic areas, and especially in CKD and ESRD populations.
To learn more about DCR, visit www.davitaclinicalresearch.com.

Contact:

DaVita Inc.
Bianca Violante, 303-876-6614
Bianca.Violante@DaVita.com
 
Press spacebar to pause and continue. Press esc to stop.